Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-NT: Strategy to Prevent Vancomycin-Induced Nephrotoxicity
NCT01734694Phase 4Terminated
- Sponsor
- Henry Ford Health
- Start
- Oct 2011
- Primary completion
- Sep 2012
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftaroline fosamil, daptomycin, linezolid in pneumonia, osteomyelitis (OM), septic arthritis, endocarditis (IE), Bacteremia, sponsored by Henry Ford Health. Started Oct 2011; status: terminated.
02
Drugs
ceftaroline fosamildaptomycinlinezolid
03
Conditions
pneumoniaosteomyelitis (OM)septic arthritisendocarditis (IE)Bacteremia
Beyond the preview
Go deeper on NCT01734694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734694.